Abstract
Recent experimental and clinical observations have suggested that host antitumor immunobiological resistance is generated by interactions between cytokines and immunomodulating hormones. In particular, it has been shown that the pineal hormone melatonin (MLT), whose oncostatic and immunomodulating activities have been well documented, may enhance the in vivo antitumor efficacy of interleukin-2 (IL-2). This study reports the results obtained up to now in untreatable advanced solid tumor patients, treated by neuroimmunotherapy with low-dose IL-2 plus MLT. The study included 342 advanced solid tumor patients with a life expectancy of less than 6 months who had not responded to previous chemotherapy or who were affected by neoplasms for which no effective standard therapy is available. Non-small cell lung cancer and gastrointestinal tract tumors were the neoplasms most frequently detected in our patients. IL-2 was given subcutaneously at 3 million IU/day in the evening for 6 days/week for 4 weeks, corresponding to one cycle. MLT was given orally at 40 mg/day in the evening, every day starting 7 days prior to IL-2. In nonprogressing patients, a second cycle was repeated after a 21-day rest period; then, patients underwent a maintenance treatment consisting of 1 week of therapy every month until progression. Patients were considered as evaluable when they received at least one cycle. Of the 342 patients, 320 were evaluable. Objective tumor regressions were achieved in 53/320 (17%) patients, consisting of four complete responses and 49 partial responses. The median duration of response was 9 months. Most responses were observed in lung cancer, hepatocarcinoma, pancreatic cancer, gastric cancer, and endocrine tumors. A survival longer than 1 year was achieved in 128/320 (40%) patients, and the percentage rate of survival at 1 year was significantly higher in the responders than in the nonresponders. Toxicity was low in all patients, fever being the only relevant side-effect This pilot clinical study shows that the concomitant administration of the pineal hormone MLT may make IL-2 effective in advanced solid tumors which generally do not respond to IL-2 alone, and suggests that the application of psychoneuroimmune knowledge to IL-2 cancer immunotherapy may represent a promising new strategy to enhance the clinical efficacy of cancer biotherapies with cytokines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alleva DG, Burger CJ, Elgert KD (1994) Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta and prostaglandin E2 J Immunol 153:1674- 1686
Atzpodien J, Kirchner H (1990) Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68:1–11
Aubert C, Jauniaud P, Lecalvez J (1980) Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting. J Neural Transm 47: 121–130
Chouaib S, Fradelizi D (1982) The mechanisms of inhibition of human IL-2 production. J Immunol 129: 2463–2467
Del Gobbo V, Libri V, Villani R, Callo R, Nisticò G (1989) Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. J Immunopharmacol 11:567–571
Dillman RO, Oldham RK, Tauer KW, Barth NM, Blumenschein G, Arnold J, Birch R, West WH (1991) Continous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a national biotherapy study group trial. J Clin Oncol 9:1233–1240
Iguchi H, Kato KI, Ibayashi H (1982) Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metabol 55: 27–29
Jancovic BD (1994) Neuroimmunomodulation. From phenomenology to molecular evidence. Ann N Y Acad Sci 741:1–38
Krigel RL, Padavic-Shaller KA, Rudolph AR, Konrad M, Bradley EC, Comis RL (1990) Renal cell carcinoma: treatments with recombinant interleukin-2 plus beta-interferon. J Clin Oncol 8: 460–467
Lissoni P (1995) Importance of interleukin-2 in cancer therapy. Adv Cancer Ther 8: 1–4
Lissoni P, Viviani S, Bajetta E, Buzzoni R, Barreca A. Mauri R, Resentini M, Morabito F, Esposti D, Esposti G, Fraschini F (1985) A clinical study of the pineal gland activity in oncologic patients. Cancer 57: 837–842
Lissoni P, Barni S, Archili C, Cattaneo G, Rovelli F, Conti A, Maestroni GJM, Tancini G (1990) Endocrine effects of a 24-hours intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Res 10: 753–758
Lissoni P, Tisi E, Brivio F, Barni S, Rovelli F, Perego M, Tancini G (1991) Increase of soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer 27: 1014–1016
Lissoni P, Tisi E, Brivio F, Ardizzoia A, Crispino S, Barni S, Tancini G, Conti A, Maestroni GJM (1991a) Modulation of interleukin-2 macrophage activation in cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents 5: 154–156
Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Archili C, Vaghi M, Tancini G (1992) Secondline therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 28: 92–96
Lissoni P, Ardizzoia A, Barni S, Rovelli F, Pittalis S, Perego M, Tisi E, Brivio F, Tancini G (1992a) Soluble interleukin-2 receptor as a marker of macrophage activation in cancer patients. Med Biol Env 20: 209–213
Lissoni P, Barni S, Rovelli F, Brivio F, Ardizzoia A, Tancini G, Conti A, Maestroni GJM (1993) Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur J Cancer 29 A: 185–189
Lissoni P, Barni S, Ardizzoia A, Andres M, Scardino E, Cardellini P, Della Bitta R, Tancini G (1993a) A randomized study of low dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as a first-line for metastatic renal cell carcinoma. Tumori 79: 397–400
Lissoni P, Pittalis S, Brivio F, Tisi E, Rovelli F, Ardizzoia A, Barni S, Tancini G, Giudici G, Biondi A, Conti A, Maestroni GJM (1993 b) In vitro modulatory effects of interleukin-2 on macrophage activation induced by interleukin-2. Cancer 71:2076–2081
Lissoni P, Pittalis S, Barni S, Rovelli F, Fumagalli L, Maestroni G (1997). Regulation of interleukin-2-interleukin-12 interactions by the pineal gland. Int J Thymol. 5: 443–447
Maestroni GJM, Conti A, Pierpaoli W (1988) Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann N Y Acad Sci. 521: 140–145
Matsuda T, Hirano T (1990) Interleukin-6 (IL-6). Biotherapy 2: 363–373
Moore KW, O’Garra A, De Waal-Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Ann Rev Immunol. 11: 165–190
Panerai AE (1993) Lymphocytes as a source of hormones and peptides. J Endocrinol Invest. 16: 549–557
Plotnikoff NP, Miller GC (1983) Enkephalins as immunomodulators. Int J Immunopharmacol 5: 437–441
Redman BG, Flaherty L, Chou TH, Al-Katib A, Kraut M, Martino S, Chen B, Kaplan J, Valdivieso M (1990) A phase I trial of recombinant interleukin-2 combined with recombinant interferon- gamma in patients with cancer. J Clin Oncol 8: 1269–1276
Regelson W, Pierpaoli W (1987) Melatonin: a rediscovered antitumor hormone? Cancer Invest 5: 379–385
Rodgers S, Rees RC, Hancock BW (1994) Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin-2 (rhIL-2) therapy. Br J Hematol 86: 746–753
Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180–199
Schiller JH, Morgan-Ihrig C, Levitt ML (1995) Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol 18:47–51
Stein RC, Malkovska V, Morgan S, Galazka A, Aniszewski C; Roy SE, Shearer RJ, Marsden RA, Bevan D, Gordon-Smith EC, Coombs RC (1991) The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interelukin-2. Br J Cancer. 63: 275–278
Sze SF, Ng TB, Liu WK (1993) Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res. 14: 27–33
Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joeux I, Pouillart P, Fridman WH (1994) Serum interleukin-6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 69: 911–913
Viviani S, Bidoli P, Spinazzé S, Rovelli F, Lissoni P (1992) Normalizatio of the light/dark rhytm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer. J Pineal Res. 12: 114–117
Wanebo HJ, Pace R, Hargett S, Katz D, Sando J (1996) Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer 57: 656–662
Whittington R, Faulds D (1993) Interleukin-2. Drugs 46: 446–514
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lissoni, P. (2001). Efficacy of Melatonin in the Immunotherapy of Cancer Using lnterleukin-2. In: Bartsch, C., Bartsch, H., Blask, D.E., Cardinali, D.P., Hrushesky, W.J.M., Mecke, D. (eds) The Pineal Gland and Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59512-7_26
Download citation
DOI: https://doi.org/10.1007/978-3-642-59512-7_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64003-2
Online ISBN: 978-3-642-59512-7
eBook Packages: Springer Book Archive